TWI487684B - Method for preparing a hardened calcium sulfate dihydrate block and use thereof - Google Patents
Method for preparing a hardened calcium sulfate dihydrate block and use thereof Download PDFInfo
- Publication number
- TWI487684B TWI487684B TW099135637A TW99135637A TWI487684B TW I487684 B TWI487684 B TW I487684B TW 099135637 A TW099135637 A TW 099135637A TW 99135637 A TW99135637 A TW 99135637A TW I487684 B TWI487684 B TW I487684B
- Authority
- TW
- Taiwan
- Prior art keywords
- hpo
- paste
- aqueous solution
- phosphate
- calcium sulphate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 96
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 title claims description 26
- 239000000243 solution Substances 0.000 claims description 99
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 72
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 57
- 238000007654 immersion Methods 0.000 claims description 47
- 229910019142 PO4 Inorganic materials 0.000 claims description 46
- 239000010452 phosphate Substances 0.000 claims description 46
- 239000007788 liquid Substances 0.000 claims description 45
- 239000007864 aqueous solution Substances 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 41
- 235000011132 calcium sulphate Nutrition 0.000 claims description 35
- 239000011734 sodium Substances 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 25
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 claims description 21
- 238000005470 impregnation Methods 0.000 claims description 16
- 239000011148 porous material Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 239000001175 calcium sulphate Substances 0.000 claims description 8
- 229940085991 phosphate ion Drugs 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 241000872931 Myoporum sandwicense Species 0.000 claims description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229930182480 glucuronide Natural products 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 235000016337 monopotassium tartrate Nutrition 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 239000003361 porogen Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- -1 potassium glucuronide Chemical class 0.000 claims description 3
- LJCNRYVRMXRIQR-UHFFFAOYSA-L potassium sodium tartrate Chemical compound [Na+].[K+].[O-]C(=O)C(O)C(O)C([O-])=O LJCNRYVRMXRIQR-UHFFFAOYSA-L 0.000 claims description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 235000011151 potassium sulphates Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 235000008486 nectar Nutrition 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 239000004568 cement Substances 0.000 description 37
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000000399 orthopedic effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002639 bone cement Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 210000004262 dental pulp cavity Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000008152 sclerosing solution Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 239000002672 zinc phosphate cement Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Description
本發明係關於一種由半水硫酸鈣粉末及水溶液的糊狀物製備二水硫酸鈣硬塊的方法,而且係關於在矯形外科治療或牙科治療(例如,根管治療)中使用該硬化的二水硫酸鈣的方法。The present invention relates to a method for preparing a calcium sulphate dihydrate from a paste of calcium sulphate hemihydrate powder and an aqueous solution, and relates to the use of the hardened dihydrate in orthopedic treatment or dental treatment (for example, root canal treatment) Method of calcium sulfate.
對於許多矯形外科應用,二水硫酸鈣由於其不足的壓縮強度及/或與磷酸鈣移植材料相比太高的溶解速率而非理想的移植材料。再者,半水硫酸鈣骨水泥之一主要缺點為其傳統上具有不夠長而無法作業的工作時間及固化時間。因此,研究人員已經嘗試多種不同方法(但是仍未成功)開發出具有適合的工作時間及固化時間且所得的二水硫酸鈣硬塊具有希望壓縮強度的半水硫酸鈣骨水泥。For many orthopedic applications, calcium sulfate dihydrate is not an ideal graft material due to its insufficient compressive strength and/or too high dissolution rate compared to calcium phosphate graft materials. Furthermore, one of the major drawbacks of calcium sulphate hemihydrate cement is that it has traditionally been short and unworkable during working hours and curing times. Therefore, researchers have tried a number of different methods (but have not succeeded) to develop calcium sulphate hemihydrate cement having a suitable working time and cure time and the resulting calcium sulphate dihydrate having the desired compressive strength.
本發明的主要目的在於提供一種骨水泥配方,其包含作為主要粉末部分的半水硫酸鈣粉末及一水溶液,以便使由該配方所形成的糊狀物適於作業及由該糊狀物所得的二水硫酸鈣硬塊具有改善的機械強度。The main object of the present invention is to provide a bone cement formulation comprising a calcium sulphate hemihydrate powder as a main powder portion and an aqueous solution to make the paste formed from the formulation suitable for work and from the paste. The calcium sulphate dihydrate block has improved mechanical strength.
本發明的另一目的在於提供一種使用本發明的骨水泥配方製備二水硫酸鈣硬塊的方法。Another object of the present invention is to provide a method of preparing a calcium sulphate dihydrate using the bone cement formulation of the present invention.
本發明的另一目的在於提供治療需要矯形外科治療或根管治療的病患的方法。Another object of the present invention is to provide a method of treating a patient in need of orthopedic treatment or root canal treatment.
本發明的較佳具體實施例包括(但不限於)下列項目:Preferred embodiments of the invention include, but are not limited to, the following items:
1. 一種製備二水硫酸鈣硬塊之方法,其包含混合半水硫酸鈣粉末與含磷酸根離子的水溶液以便形成一糊狀物,其中該水溶液具有低於10的pH值。A method of preparing a hard block of calcium sulphate dihydrate comprising mixing a calcium sulphate hemihydrate powder with an aqueous solution containing a phosphate ion to form a paste, wherein the aqueous solution has a pH of less than 10.
2. 如第1項之方法,其中沒有將鹼性化合物加至該水溶液、該半水硫酸鈣粉末或其糊狀物以調整其pH值。2. The method according to item 1, wherein the alkaline compound is not added to the aqueous solution, the calcium sulfate hemihydrate powder or a paste thereof to adjust the pH thereof.
3. 如第1項之方法,其中在該混合作用之前該水溶液具有低於50℃的溫度。3. The method of item 1, wherein the aqueous solution has a temperature below 50 °C prior to the mixing.
4. 如第3項之方法,其中該混合作用係於低於50℃的溫度下進行。4. The method of item 3, wherein the mixing is carried out at a temperature below 50 °C.
5.如第3項之方法,其中該粉末及該水溶液的糊狀物具有低於50℃的溫度。5. The method of item 3, wherein the powder and the paste of the aqueous solution have a temperature of less than 50 °C.
6.如第1項之方法,其中沒有對該水溶液、該半水硫酸鈣粉末或其糊狀物施以加熱以將其溫度提高至等於或高於50℃。6. The method of item 1, wherein the aqueous solution, the calcium sulphate hemihydrate powder or the paste thereof is not heated to raise the temperature to be equal to or higher than 50 °C.
7. 如第6項之方法,其中該水溶液具有低於1.0 M的磷酸根離子濃度。7. The method of item 6, wherein the aqueous solution has a phosphate ion concentration of less than 1.0 M.
8. 如第7項之方法,其中該濃度為0.01 M至0.5 M。8. The method of item 7, wherein the concentration is from 0.01 M to 0.5 M.
9. 如第1項之方法,其中該混合係以0.20 cc/g至0.60 cc/g的液體對粉末比進行。9. The method of item 1, wherein the mixing is carried out at a liquid to powder ratio of from 0.20 cc/g to 0.60 cc/g.
10. 如第9項之方法,其中該液體對粉末比為0.30 cc/g至0.50 cc/g。10. The method of item 9, wherein the liquid to powder ratio is from 0.30 cc/g to 0.50 cc/g.
11. 如第1項之方法,其中該水溶液為(NH4 )3 PO4 、(NH4 )2 HPO4 、NH4 H2 PO4 、K3 PO4 、K2 HPO4 、KH2 PO4 、Na3 PO4 、Na2 HPO4 、NaH2 PO4 、H3 PO4 或其混合物的水溶液。11. The method of item 1, wherein the aqueous solution is (NH 4 ) 3 PO 4 , (NH 4 ) 2 HPO 4 , NH 4 H 2 PO 4 , K 3 PO 4 , K 2 HPO 4 , KH 2 PO 4 An aqueous solution of Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 , H 3 PO 4 or a mixture thereof.
12. 如第11項之方法,其中該水溶液為(NH4 )3 PO4 、(NH4 )2 HPO4 、NH4 H2 PO4 或其混合物的水溶液。12. The method of item 11, wherein the aqueous solution is an aqueous solution of (NH 4 ) 3 PO 4 , (NH 4 ) 2 HPO 4 , NH 4 H 2 PO 4 or a mixture thereof.
13. 如第1項之方法,其中該水溶液或該半水硫酸鈣粉末另外包含活細胞、生長因子或藥物。13. The method of item 1, wherein the aqueous solution or the calcium sulphate hemihydrate powder additionally comprises living cells, growth factors or drugs.
14. 如第1項之方法,其中該半水硫酸鈣粉末為α-型半水硫酸鈣粉末。14. The method of item 1, wherein the calcium sulphate hemihydrate powder is an alpha-type calcium sulphate hemihydrate powder.
15. 如第1項之方法,其另外包含把該糊狀物引至洞或穴並且讓該糊狀物變成在原處固化以在該洞或穴中形成二水硫酸鈣硬塊。15. The method of clause 1, further comprising introducing the paste to a hole or cavity and allowing the paste to solidify in situ to form a calcium sulphate dihydrate block in the hole or cavity.
16. 如第1項之方法,其另外包含使該糊狀物在鑄模中成形,及移除該鑄模以形成二水硫酸鈣硬塊。16. The method of item 1, further comprising shaping the paste in a mold and removing the mold to form a hard block of calcium sulfate dihydrate.
17. 如第16項之方法,其另外包含在該糊狀物固化之前加壓該鑄模中的糊狀物以從該糊狀物移除一部分液體,使得該糊狀物的液體對粉末比降低。17. The method of clause 16, further comprising pressurizing the paste in the mold to cure a portion of the liquid from the paste prior to curing of the paste, such that the liquid to powder ratio of the paste is reduced .
18. 如第17項之方法,其中應用於該鑄模中的糊狀物的壓力為約1 MPa至500 MPa,較佳為100 MPa至500 MPa。18. The method of item 17, wherein the pressure applied to the paste in the mold is from about 1 MPa to 500 MPa, preferably from 100 MPa to 500 MPa.
19. 如第16項之方法,其另外包含以浸漬液浸漬該硬塊一段時間,使得從該浸漬液移出所得的浸漬塊的壓縮強度與沒經過該浸漬處理的硬塊的壓縮強度相比有所提高。19. The method of item 16, further comprising impregnating the lumps with an immersion liquid for a period of time such that the compressive strength of the resulting impregnated mass removed from the immersion liquid is increased as compared to the compressive strength of the lumps not subjected to the immersion treatment. .
20. 如第19項之方法,其中該浸漬液為含磷酸根溶液。20. The method of item 19, wherein the immersion liquid is a phosphate-containing solution.
21. 如第20項之方法,其中該含磷酸根溶液為(NH4 )3 PO4 、(NH4 )2 HPO4 、NH4 H2 PO4 、K3 PO4 、K2 HPO4 、KH2 PO4 、Na3 PO4 、Na2 HPO4 、NaH2 PO4 或H3 PO4 的水溶液。21. The method of item 20, wherein the phosphate-containing solution is (NH 4 ) 3 PO 4 , (NH 4 ) 2 HPO 4 , NH 4 H 2 PO 4 , K 3 PO 4 , K 2 HPO 4 , KH An aqueous solution of 2 PO 4 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 or H 3 PO 4 .
22. 如第20項之方法,其中該含磷酸根溶液具有約0.1 M至約6 M,較佳約1 M至約3 M的磷酸根濃度。22. The method of clause 20, wherein the phosphate-containing solution has a phosphate concentration of from about 0.1 M to about 6 M, preferably from about 1 M to about 3 M.
23. 如第20項之方法,其中該浸漬作用係於約0℃的溫度下進行。23. The method of item 20, wherein the impregnation is carried out at a temperature of about 0 °C.
24. 如第1項之方法,其另外包含混合造孔劑與該粉末或與該糊狀物;使該糊狀物在鑄模中成形;移除該鑄模以形成該造孔劑埋在裡面的二水硫酸鈣硬塊;及把該造孔劑埋在裡面的二水硫酸鈣硬塊沉浸在沉浸液中使該造孔劑溶解於該沉浸液,在該二水硫酸鈣硬塊內產生細孔,以便形成多孔性硬塊。24. The method of item 1, further comprising mixing a pore former with the powder or with the paste; forming the paste in a mold; removing the mold to form the pore former buried therein a slab of calcium sulphate dihydrate; and a hard block of calcium sulphate dihydrate embedded in the porogen is immersed in the immersion liquid to dissolve the porogen in the immersion liquid, and pores are generated in the slab of calcium sulphate dihydrate, so that A porous lumps are formed.
25. 如第24項之方法,其中該造孔劑係選自由下列物質所組成的群組:LiCl、KCl、NaCl、MgCl2 、CaCl2 、NaIO3 、KI、Na3 PO4 、K3 PO4 、Na2 CO3 、胺基酸-鈉鹽、胺基酸-鉀鹽、葡萄糖、多醣類、脂肪酸-鈉鹽、脂肪酸-鉀鹽、酸式酒石酸鉀(KHC4 H4 O6 )、碳酸鉀、葡萄糖醛酸鉀(KC6 H11 O7 )、酒石酸鉀-鈉(KNaC4 H4 O6 ‧4 H2 O)、硫酸鉀(K2 SO4 )、硫酸鈉、乳酸鈉及甘露糖醇。25. The method of item 24, wherein the pore former is selected from the group consisting of LiCl, KCl, NaCl, MgCl 2 , CaCl 2 , NaIO 3 , KI, Na 3 PO 4 , K 3 PO 4 , Na 2 CO 3 , amino acid-sodium salt, amino acid-potassium salt, glucose, polysaccharide, fatty acid-sodium salt, fatty acid-potassium salt, potassium acid tartrate (KHC 4 H 4 O 6 ), Potassium carbonate, potassium glucuronide (KC 6 H 11 O 7 ), potassium tartrate-sodium (KNaC 4 H 4 O 6 ‧ 4 H 2 O), potassium sulfate (K 2 SO 4 ), sodium sulfate, sodium lactate and mannose alcohol.
26. 如第24項之方法,其中該沉浸液為酸性水溶液、鹼性水溶液、生理溶液、有機溶劑或水。26. The method of item 24, wherein the immersion liquid is an acidic aqueous solution, an alkaline aqueous solution, a physiological solution, an organic solvent or water.
27. 如第26項之方法,其中該沉浸液具有約0.1 M至約6 M,較佳約1 M至約3 M的磷酸根濃度之含磷酸根溶液。27. The method of clause 26, wherein the immersion solution has a phosphate-containing solution having a phosphate concentration of from about 0.1 M to about 6 M, preferably from about 1 M to about 3 M.
28. 如第27項之方法,其中該含磷酸根溶液為(NH4 )3 PO4 、(NH4 )2 HPO4 、NH4 H2 PO4 、K3 PO4 、K2 HPO4 、KH2 PO4 、Na3 PO4 、Na2 HPO4 、NaH2 PO4 或H3 PO4 的水溶液。28. The method of item 27, wherein the phosphate-containing solution is (NH 4 ) 3 PO 4 , (NH 4 ) 2 HPO 4 , NH 4 H 2 PO 4 , K 3 PO 4 , K 2 HPO 4 , KH An aqueous solution of 2 PO 4 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 or H 3 PO 4 .
29. 如第27項之方法,其中該沉浸液為水。29. The method of item 27, wherein the immersion liquid is water.
30. 如第24項之方法,其另外包含以浸漬液浸漬該多孔性硬塊一段時間,使得從該浸漬液移出所得的浸漬多孔性硬塊的壓縮強度與沒經過該浸漬處理的多孔性硬塊的壓縮強度相比有所提高。30. The method of item 24, further comprising impregnating the porous lumps with an immersion liquid for a period of time such that the compressive strength of the impregnated porous lumps removed from the immersion liquid and the compression of the porous lumps not subjected to the immersion treatment The strength is improved compared to the strength.
31. 如第30項之方法,其中該浸漬液為含磷酸根溶液。31. The method of item 30, wherein the immersion liquid is a phosphate-containing solution.
32. 如第31項之方法,其中該含磷酸根溶液為(NH4 )3 PO4 、(NH4 )2 HPO4 、NH4 H2 PO4 、K3 PO4 、K2 HPO4 、KH2 PO4 、Na3 PO4 、Na2 HPO4 、NaH2 PO4 或H3 PO4 的水溶液。32. The method of item 31, wherein the phosphate-containing solution is (NH 4 ) 3 PO 4 , (NH 4 ) 2 HPO 4 , NH 4 H 2 PO 4 , K 3 PO 4 , K 2 HPO 4 , KH An aqueous solution of 2 PO 4 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 or H 3 PO 4 .
33. 如第31項之方法,其中該含磷酸根溶液具有約0.1 M至約6 M,較佳約1 M至約3 M的磷酸根濃度。33. The method of clause 31, wherein the phosphate-containing solution has a phosphate concentration of from about 0.1 M to about 6 M, preferably from about 1 M to about 3 M.
34. 如第27項之方法,其另外包含在活細胞的懸浮液或生長因子或藥物的溶液中浸漬該多孔性硬塊以將該等活細胞、生長因子或藥物沉積在該多孔性硬塊上。34. The method of clause 27, further comprising impregnating the porous lumps in a suspension of living cells or a solution of growth factors or drugs to deposit the living cells, growth factors or drugs on the porous lumps.
35. 如第24項之方法,其中該多孔性硬塊具有50至90體積%的孔隙率。The method of item 24, wherein the porous lumps have a porosity of 50 to 90% by volume.
36. 一種治療病患之方法,其包含混合半水硫酸鈣粉末與含磷酸根離子的水溶液以便形成糊狀物;及在該治療所需下以該糊狀物填充在該病患的骨頭之洞或穴中,該糊狀物在該洞或穴內固化。36. A method of treating a patient comprising mixing a calcium sulphate hemihydrate powder with an aqueous solution containing phosphate ions to form a paste; and filling the bone of the patient with the paste as needed for the treatment In a hole or hole, the paste solidifies in the hole or cavity.
37. 如第36項之方法,其中該治療為矯形外科治療或牙科治療。37. The method of clause 36, wherein the treatment is orthopedic or dental treatment.
38. 一種治療病患之方法,其包含混合半水硫酸鈣粉末與含磷酸根離子的水溶液以便形成糊狀物;由該糊狀物形成二水硫酸鈣硬塊;及在該治療所需下把該硬塊植入該病患體內。38. A method of treating a patient comprising mixing a calcium sulphate hemihydrate powder with an aqueous solution containing phosphate ions to form a paste; forming a lumps of calcium sulphate dihydrate from the syrup; and The lumps are implanted into the patient.
39. 如第38項之方法,其中該治療為矯形外科治療或牙科治療。39. The method of clause 38, wherein the treatment is orthopedic or dental treatment.
40. 如第39項之方法,其中該植入作用包含把該硬塊擊碎成屑狀物及以該屑狀物填充該病患的骨頭中之洞或穴。40. The method of clause 39, wherein the implanting comprises breaking the lumps into crumbs and filling the holes or holes in the bone of the patient with the crumbs.
41.如第39項之方法,其中該二水硫酸鈣硬塊的形成包含使該糊狀物在鑄模中成形,及移除該鑄模以形成二水硫酸鈣硬塊。41. The method of clause 39, wherein the forming of the calcium sulphate dihydrate comprises forming the paste in a mold and removing the mold to form a calcium sulphate dihydrate.
42. 如第41項之方法,其中該二水硫酸鈣硬塊的形成另外包含在該糊狀物固化之前加壓該鑄模中的糊狀物以從該糊狀物移除一部分液體,使得該糊狀物的液體對粉末比降低。42. The method of clause 41, wherein the forming of the calcium sulphate dihydrate block further comprises pressurizing the paste in the mold to cure a portion of the liquid from the paste prior to curing of the paste, such that the paste The liquid to powder ratio is reduced.
43. 如第42項之方法,其中應用於該鑄模中的糊狀物的壓力為約1 MPa至500 MPa,較佳為100 MPa至500 MPa。43. The method of item 42, wherein the pressure applied to the paste in the mold is from about 1 MPa to 500 MPa, preferably from 100 MPa to 500 MPa.
44. 如第41項之方法,其中該二水硫酸鈣硬塊的形成另外包含以浸漬液浸漬該硬塊一段時間,使得從該浸漬液移出所得的浸漬塊的壓縮強度與沒經過該浸漬處理的硬塊的壓縮強度相比有所提高。44. The method of item 41, wherein the forming of the calcium sulphate dihydrate syrup further comprises impregnating the lumps with the immersion liquid for a period of time such that the resulting impregnated mass removed from the immersion liquid has a compressive strength and a lumps that have not undergone the immersion treatment. The compressive strength is improved compared to that.
45. 如第44項之方法,其中該浸漬液為含磷酸根溶液。45. The method of item 44, wherein the immersion liquid is a phosphate-containing solution.
46. 如第45項之方法,其中該含磷酸根溶液為(NH4 )3 PO4 、(NH4 )2 HPO4 、NH4 H2 PO4 、K3 PO4 、K2 HPO4 、KH2 PO4 、Na3 PO4 、Na2 HPO4 、NaH2 PO4 或H3 PO4 的水溶液。46. The method of item 45, wherein the phosphate-containing solution is (NH 4 ) 3 PO 4 , (NH 4 ) 2 HPO 4 , NH 4 H 2 PO 4 , K 3 PO 4 , K 2 HPO 4 , KH An aqueous solution of 2 PO 4 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 or H 3 PO 4 .
47. 如第45項之方法,其中該含磷酸根溶液具有約0.1 M至約6 M,較佳約1 M至約3 M的磷酸根濃度。47. The method of clause 45, wherein the phosphate-containing solution has a phosphate concentration of from about 0.1 M to about 6 M, preferably from about 1 M to about 3 M.
48. 如第45項之方法,其中該浸漬作用係於約0℃的溫度下進行。48. The method of item 45, wherein the impregnation is carried out at a temperature of about 0 °C.
49. 如第38項之方法,其另外包含混合造孔劑與該粉末或與該糊狀物,其中該二水硫酸鈣硬塊的形成包含使該糊狀物在鑄模中成形;移除該鑄模以形成該造孔劑埋在裡面的二水硫酸鈣硬塊;及把該造孔劑埋在裡面的二水硫酸鈣硬塊沉浸在沉浸液中使該造孔劑溶解於該沉浸液,在該二水硫酸鈣硬塊內產生細孔,以便形成多孔性硬塊,於是該植入包含在該治療所需下把該多孔性硬塊植入該病患體內。49. The method of clause 38, further comprising mixing a pore former with the powder or with the paste, wherein the forming of the calcium sulphate dihydrate comprises forming the paste in a mold; removing the mold Forming the hard block of calcium sulphate dihydrate buried in the pore-forming agent; and immersing the hard block of calcium sulphate dihydrate in which the pore-forming agent is buried in the immersion liquid to dissolve the pore-forming agent in the immersion liquid, The pores are formed in the calcium sulphate hard block to form a porous lumps, and the implant contains the porous lumps implanted into the patient under the treatment.
50. 如第49項之方法,其中該植入包含把該多孔性硬塊擊碎成屑狀物及以該屑狀物填充在該病患的骨頭中之洞或穴。50. The method of clause 49, wherein the implanting comprises crushing the porous lumps into crumbs and filling the holes or holes in the bones of the patient with the crumbs.
51. 如第50項之方法,其中該造孔劑係選自由下列物質所組成的群組:LiCl、KCl、NaCl、MgCl2 、CaCl2 、NaIO3 、KI、Na3 PO4 、K3 PO4 、Na2 CO3 、胺基酸-鈉鹽、胺基酸-鉀鹽、葡萄糖、多醣類、脂肪酸-鈉鹽、脂肪酸-鉀鹽、酸式酒石酸鉀(KHC4 H4 O6 )、碳酸鉀、葡萄糖醛酸鉀(KC6 H11 O7 )、酒石酸鉀-鈉(KNaC4 H4 O6 ‧4 H2 O)、硫酸鉀(K2 SO4 )、硫酸鈉、乳酸鈉及甘露糖醇。51. The method of item 50, wherein the pore former is selected from the group consisting of LiCl, KCl, NaCl, MgCl 2 , CaCl 2 , NaIO 3 , KI, Na 3 PO 4 , K 3 PO 4 , Na 2 CO 3 , amino acid-sodium salt, amino acid-potassium salt, glucose, polysaccharide, fatty acid-sodium salt, fatty acid-potassium salt, potassium acid tartrate (KHC 4 H 4 O 6 ), Potassium carbonate, potassium glucuronide (KC 6 H 11 O 7 ), potassium tartrate-sodium (KNaC 4 H 4 O 6 ‧ 4 H 2 O), potassium sulfate (K 2 SO 4 ), sodium sulfate, sodium lactate and mannose alcohol.
52. 如第50項之方法,其中該沉浸液為酸性水溶液、鹼性水溶液、生理溶液、有機溶劑或水。52. The method of item 50, wherein the immersion liquid is an acidic aqueous solution, an alkaline aqueous solution, a physiological solution, an organic solvent or water.
53. 如第52項之方法,其中該沉浸液為具有約0.1 M至約6 M,較佳約1 M至約3 M的磷酸根濃度之含磷酸根溶液。53. The method of clause 52, wherein the immersion fluid is a phosphate-containing solution having a phosphate concentration of from about 0.1 M to about 6 M, preferably from about 1 M to about 3 M.
54. 如第53項之方法,其中該含磷酸根溶液為(NH4 )3 PO4 、(NH4 )2 HPO4 、NH4 H2 PO4 、K3 PO4 、K2 HPO4 、KH2 PO4 、Na3 PO4 、Na2 HPO4 、NaH2 PO4 或H3 PO4 的水溶液。54. The method of item 53, wherein the phosphate-containing solution is (NH 4 ) 3 PO 4 , (NH 4 ) 2 HPO 4 , NH 4 H 2 PO 4 , K 3 PO 4 , K 2 HPO 4 , KH An aqueous solution of 2 PO 4 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 or H 3 PO 4 .
55. 如第53項之方法,其中該沉浸液為水。55. The method of item 53, wherein the immersion liquid is water.
56. 如第50項之方法,其另外包含以浸漬液浸漬該硬塊一段時間,使得從該浸漬液移出所得的浸漬多孔性硬塊的壓縮強度與沒經過該浸漬處理的多孔性硬塊的壓縮強度相比有所提高。56. The method of item 50, further comprising impregnating the lumps with an immersion liquid for a period of time such that the compressive strength of the impregnated porous lumps removed from the immersion liquid is comparable to the compressive strength of the porous lumps not subjected to the immersion treatment. More than that.
57. 如第56項之方法,其中該浸漬液為含磷酸根溶液。57. The method of item 56, wherein the immersion liquid is a phosphate-containing solution.
58. 如第57項之方法,其中該含磷酸根溶液為(NH4 )3 PO4 、(NH4 )2 HPO4 、NH4 H2 PO4 、K3 PO4 、K2 HPO4 、KH2 PO4 、Na3 PO4 、Na2 HPO4 、NaH2 PO4 或H3 PO4 的水溶液。58. The method of item 57, wherein the phosphate-containing solution is (NH 4 ) 3 PO 4 , (NH 4 ) 2 HPO 4 , NH 4 H 2 PO 4 , K 3 PO 4 , K 2 HPO 4 , KH An aqueous solution of 2 PO 4 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 or H 3 PO 4 .
59. 如第57項之方法,其中該含磷酸根溶液具有約0.1 M至約6 M,較佳約1 M至約3 M的磷酸根濃度。59. The method of clause 57, wherein the phosphate-containing solution has a phosphate concentration of from about 0.1 M to about 6 M, preferably from about 1 M to about 3 M.
60. 如第49項之方法,其另外包含在活細胞的懸浮液或生長因子或藥物的溶液中浸漬該多孔性硬塊以將該等活細胞、生長因子或藥物沉積在該多孔性硬塊上。60. The method of clause 49, further comprising impregnating the porous lumps in a suspension of living cells or a solution of growth factors or drugs to deposit the living cells, growth factors or drugs on the porous lumps.
61.如第49項之方法,其中該多孔性硬塊具有50至90體積%的孔隙率。The method of item 49, wherein the porous lumps have a porosity of 50 to 90% by volume.
本發明提供一種延長半水硫酸鈣糊狀物的工作時間及固化時間的技術,其係藉由混合半水硫酸鈣粉末與含磷酸根離子的水溶液,使得該糊狀物適於作業而且由該糊狀物所得的二水硫酸鈣硬塊具有改善的機械強度。根據本發明所提供的骨水泥配方係由半水硫酸鈣粉末、含磷酸根離子的水溶液及一或更多任意功能性組成分例如活細胞、生長因子、藥物或造孔劑構成。The present invention provides a technique for extending the working time and curing time of a calcium sulphate hemihydrate paste by mixing a calcium sulphate hemihydrate powder and an aqueous solution containing a phosphate ion, so that the paste is suitable for operation and The calcium sulphate dihydrate obtained from the paste has improved mechanical strength. The bone cement formulation provided in accordance with the present invention consists of calcium sulfate hemihydrate powder, an aqueous solution containing phosphate ions, and one or more optional functional components such as living cells, growth factors, drugs or pore forming agents.
本發明將透過下列實施例獲得較好的理解,該等實施例僅為例示性而且不欲以任何方式限制。The invention will be better understood by the following examples, which are merely illustrative and are not intended to be limited in any way.
該硫酸鈣水泥糊狀物係藉由合宜的液體/粉末比(舉例來說,0.35cc/g)混合適當量的CSH粉末及硬化溶液(舉例來說,磷酸二氫二銨或磷酸氫二鉀)而製備。The calcium sulfate cement paste is prepared by mixing an appropriate amount of CSH powder and a hardening solution (for example, diammonium phosphate or dipotassium hydrogen phosphate) by a suitable liquid/powder ratio (for example, 0.35 cc/g). ) prepared.
於合宜的L/P比例下在球磨機中均勻混合適當量的CSH粉末及硬化溶液以形成硫酸鈣水泥糊狀物.The appropriate amount of CSH powder and hardening solution are uniformly mixed in a ball mill at a suitable L/P ratio to form a calcium sulfate cement paste.
在完全硬化之前,在合宜的壓力(舉例來說,450Kgf)之下把該糊狀物放在鑄模中以將一部分硬化溶液擠出該糊狀物以形成硬化緻密塊。等到從該鑄模移除之後,把一組硬化樣品放在防潮容器中1天。另外把另一組樣品浸漬於合宜溫度(舉例來說,37℃)下的浸漬溶液(舉例來說,(NH4 )2 HPO4 或K2 HPO4 )中一段時間(舉例來說,1天),接著在50℃的烘箱中乾燥1天。Prior to complete hardening, the paste is placed in a mold under a suitable pressure (for example, 450 Kgf) to extrude a portion of the hardening solution from the paste to form a hardened dense mass. After removing from the mold, a set of hardened samples were placed in a moisture-proof container for 1 day. Another set of samples is immersed in an impregnation solution (for example, (NH 4 ) 2 HPO 4 or K 2 HPO 4 ) at a suitable temperature (for example, 37 ° C) for a period of time (for example, 1 day) Then, it was dried in an oven at 50 ° C for 1 day.
以合宜的KCl/CSH比例(舉例來說以重量計為1:1或1.5:1)及合宜的液體/粉末比(舉例來說,0.35 cc/g)均勻混合適當量的CSH粉末、粉末、造孔粒子(舉例來說KCl)及硬化溶液以形成KCl/CSH水泥糊狀物。Mixing the appropriate amount of CSH powder, powder, and the appropriate KCl/CSH ratio (for example, 1:1 or 1.5:1 by weight) and a suitable liquid/powder ratio (for example, 0.35 cc/g) The pore-forming particles (for example, KCl) and the hardening solution are formed to form a KCl/CSH cement paste.
在完全硬化之前,在合宜的壓力(舉例來說,450 Kgf)之下把該KCl/CSH水泥糊狀物放在鑄模中以將一部分硬化溶液擠出該糊狀物以形成硬化緻密塊。等到從該鑄模移除之後,把該硬化緻密塊樣品沉浸於去離子水中一段時間(舉例來說,3天)使該等造孔粒子能被洗出該緻密塊以形成硫酸鈣多孔性硬塊,接著在50℃的烘箱中乾燥1天。Prior to complete hardening, the KCl/CSH cement paste is placed in a mold under a suitable pressure (for example, 450 Kgf) to squeeze a portion of the hardening solution out of the paste to form a hardened dense mass. After the removal from the mold, the hardened dense block sample is immersed in deionized water for a period of time (for example, 3 days) to enable the pore-forming particles to be washed out of the dense block to form a porous slab of calcium sulfate. It was then dried in an oven at 50 ° C for 1 day.
把一組多孔性硬塊樣品進一步浸漬於合宜溫度(舉例來說,37℃或4℃)下的浸漬溶液(例如,(NH4 )2 HPO4 或K2 HPO4 )中一段時間以使該多孔性硬塊的強度提高,接著在50℃的烘箱中乾燥1天。為了從該等細孔內部移除剩餘的浸漬溶液,在去離子水中沖洗經浸漬的多孔性樣品一段時時(舉例來說,3天)。A set of porous hard block samples are further immersed in an impregnation solution (for example, (NH 4 ) 2 HPO 4 or K 2 HPO 4 ) at a suitable temperature (for example, 37 ° C or 4 ° C) for a period of time to make the porous The strength of the lumps was increased and then dried in an oven at 50 ° C for 1 day. To remove the remaining impregnation solution from within the pores, the impregnated porous sample is rinsed in deionized water for a period of time (for example, 3 days).
另外藉由沉浸在CaCl2 溶液中一段時間(舉例來說,3天)處理另一組樣品以進一步增進該等多孔性樣品的強度。Further, another set of samples was treated by immersing in a CaCl 2 solution for a period of time (for example, 3 days) to further enhance the strength of the porous samples.
為了測量硬化水泥的CS,等混合1分鐘之後,在0.7 MPa的壓力之下把該水泥糊狀物裝入一6 mm直徑,12 mm深的圓柱形不銹鋼鑄模中30分鐘。等到從該鑄模移除之後,把硬化的水泥樣品沉浸在保持於37℃的Hanks’生理溶液中並且每天攪動以協助保持均勻的離子濃度。沉浸之後,從該溶液移出樣品以供於樣品還是濕的情況下進行CS測試。使用桌上型機械測試儀(Shimadzu AGS-500D,東京,日本)於1.0 mm/min的十字頭(crosshead)速度下進行CS測試。該試驗方法係根據ASTM 451-99a方法。In order to measure the CS of the hardened cement, after mixing for 1 minute, the cement paste was placed in a 6 mm diameter, 12 mm deep cylindrical stainless steel mold for 30 minutes under a pressure of 0.7 MPa. After removal from the mold, the hardened cement sample was immersed in a Hanks' physiological solution maintained at 37<0>C and agitated daily to assist in maintaining a uniform ion concentration. After immersion, the sample was removed from the solution for the CS test if the sample was still wet. The CS test was performed using a desktop mechanical tester (Shimadzu AGS-500D, Tokyo, Japan) at a crosshead speed of 1.0 mm/min. The test method is in accordance with ASTM 451-99a.
到該水泥糊狀物不再能加工的時候測定水泥糊狀物的工作時間。根據關於牙齒用的磷酸鋅水泥的ISO 1566所述的標準方法測量水泥糊狀物的固化時間。當具有1 mm直徑尖頭的Vical針上裝載著400 gm的砝碼無法在該水泥表面上造成可察覺的圓形凹痕時將該水泥視為固化。The working time of the cement paste is determined when the cement paste is no longer processable. The curing time of the cement paste was measured according to the standard method described in ISO 1566 for zinc phosphate cement for teeth. The cement was considered to be cured when a 400 gm weight on a Vical needle with a 1 mm diameter tip could not cause a perceptible circular indentation on the cement surface.
使用pH酸度計(Suntex Instruments SP20004,台北,台灣)測定初期(在固化過程中)的pH變化,等該粉末及固化液混合之後立即將該pH酸度計埋在該水泥糊狀物中。在混合之後1分鐘時採集第一次的度數。持續不斷測量直到該糊狀物幾乎固化為止。每30秒採集度數直到混合之後30分鐘為止。之後接著每60秒採集度數。The pH change at the initial stage (during curing) was measured using a pH acidity meter (Suntex Instruments SP20004, Taipei, Taiwan), and the pH acidity meter was buried in the cement paste immediately after the powder and the solidified liquid were mixed. The first degree was taken 1 minute after mixing. Continue to measure until the paste is almost cured. The degree is collected every 30 seconds until 30 minutes after mixing. The degree is then collected every 60 seconds.
使用相同的pH酸度計監測沉浸該水泥糊狀物樣品的Hanks’溶液的pH值變化。等該粉末及該固化溶液混合5分鐘之後採取2 g水泥糊狀物,並且把該水泥糊狀物沉浸在20 ml測得pH值為7.05的Hanks’溶液中。整個測試過程中把該溶液保持於37℃並且持續不斷攪拌以協助維持該溶液的均勻離子濃度。The pH change of the Hanks' solution immersed in the cement paste sample was monitored using the same pH acidity meter. After the powder and the solidified solution were mixed for 5 minutes, 2 g of a cement paste was taken, and the cement paste was immersed in 20 ml of a Hanks' solution having a pH of 7.05. The solution was maintained at 37 ° C throughout the test and continued to stir to help maintain a uniform ion concentration of the solution.
根據ASTM C830-00(2006)方法,"Standard Test Methods for Apparent Porosity,Liquid Absorption,Apparent Specific Gravity,and Bulk Density of Refractory Shapes by Vacuum Pressure",測量多種不同樣品的孔隙率。The porosity of a plurality of different samples was measured according to the method of ASTM C830-00 (2006), "Standard Test Methods for Apparent Porosity, Liquid Absorption, Apparent Specific Gravity, and Bulk Density of Refractory Shapes by Vacuum Pressure".
1. 所有含有磷酸根(不論酸性或鹼性)的溶液均導致適度的WT/ST(約5至10分鐘),而所有不含磷酸根(不論酸性或鹼性)的溶液均導致太短的WT/ST(就糊狀物注射外科治療而言)。1. All solutions containing phosphate (whether acidic or basic) result in moderate WT/ST (about 5 to 10 minutes), while all solutions that do not contain phosphate (whether acidic or basic) cause too short WT/ST (for surgical treatment of paste injection).
(註釋:太短的WT/ST沒有足夠時間進行準備及/或外科治療)(Note: too short WT/ST does not have enough time for preparation and/or surgical treatment)
2. 所有含有磷酸根(不論酸性或鹼性)的溶液均得到比不含磷酸根的溶液高出許多的CS值。2. All solutions containing phosphate (whether acidic or basic) are much higher than the CS-free solution.
3. 0.0375 M的磷酸根濃度導致最高的CS值,但是由全部三個濃度(0.01875至0.075 M)所獲得的CS值均可接受。3. The phosphate concentration of 0.0375 M results in the highest CS value, but the CS values obtained from all three concentrations (0.01875 to 0.075 M) are acceptable.
*提高L/P比例以促進混合* Increase the L/P ratio to promote mixing
*提高L/P比例以促進混合* Increase the L/P ratio to promote mixing
1. 含有至多1.0 M的磷酸根濃度的(NH4 )2 HPO4 溶液得到適度的WT/ST。1. (NH 4 ) 2 HPO 4 solution containing a phosphate concentration of up to 1.0 M gives moderate WT/ST.
2. 含有至多0.1 M的磷酸根濃度的K2 HPO4 溶液得到適度的WT/ST。當K2 HPO4 濃度高於0.1 M時,WT/ST變得太長(就糊狀物注射外科治療而言)。2. A moderately WT/ST was obtained with a K 2 HPO 4 solution containing a phosphate concentration of at most 0.1 M. When the concentration of K 2 HPO 4 is higher than 0.1 M, WT/ST becomes too long (in terms of surgical treatment of paste injection).
(註釋:太長的WT/ST指示低的初期強度及硬化之前該糊狀物容易因接觸體液/血液而分散)。(Note: too long WT/ST indicates low initial strength and the paste is easily dispersed by contact with body fluid/blood before hardening).
*把L/P比例提高至0.40以促進混合* Increase the L/P ratio to 0.40 to promote mixing
1. 0.0375 M的磷酸根濃度導致最高的CS值,但是至高0.1 M的磷酸根濃度仍能得到適度的CS。1. The phosphate concentration of 0.0375 M results in the highest CS value, but a moderate CS can still be obtained at a phosphate concentration of 0.1 M.
2. 當磷酸根濃度為0.75 M時,該CS值變得比0.0375 M的CS值一半更低。2. When the phosphate concentration is 0.75 M, the CS value becomes lower than half of the CS value of 0.0375 M.
1. WT/ST值對於該硬化溶液的pH值非常敏感。1. The WT/ST value is very sensitive to the pH of the hardening solution.
2. 當含磷酸根溶液(不論是(NH4 )2 HPO4 或K2 HPO4 )具有高於約11的pH值時,WT/ST將大幅減短而變得無法接受。2. When a phosphate-containing solution (whether (NH 4 ) 2 HPO 4 or K 2 HPO 4 ) has a pH above about 11, the WT/ST will be significantly reduced and become unacceptable.
1. CS值對於該硬化溶液的pH值非常敏感。1. The CS value is very sensitive to the pH of the hardening solution.
2. 當(NH4 )2 HPO4 硬化溶液具有高於約11的pH值時,該CS值大幅降低。當其pH值達到13.0時,該CS值從其最高的CS降低68%。2. When the (NH 4 ) 2 HPO 4 hardening solution has a pH above about 11, the CS value is greatly reduced. When its pH reached 13.0, the CS value was reduced by 68% from its highest CS.
3. 當K2 HPO4 硬化溶液具有高於約12.0的pH值時,該CS值大幅降低。當其pH值達到13.0時,該CS值從其最高的CS降低67%。3. When the K 2 HPO 4 hardening solution has a pH above about 12.0, the CS value is greatly reduced. When its pH reached 13.0, the CS value was reduced by 67% from its highest CS.
混合15分鐘之後該糊狀物(混合CSH及0.0375M(NH4 )2 HPO4 )的pH值緩慢提高至介於6.5與7.0之間的範圍,組織/細胞可接受的範圍。After 15 minutes of mixing, the pH of the paste (mixed CSH and 0.0375 M(NH 4 ) 2 HPO 4 ) was slowly increased to a range between 6.5 and 7.0, tissue/cell acceptable range.
該Hanks’溶液的pH值總是介於6與7之間,組織/細胞可接受的範圍。經過14天之後,該pH值變成接近中性。The pH of the Hanks' solution is always between 6 and 7, with a tissue/cell acceptable range. After 14 days, the pH became nearly neutral.
1. 由去離子水所製備的硫酸鈣水泥的CS值遠低於另外兩種含磷酸根的硬化溶液。1. The calcium sulfate cement prepared from deionized water has a CS value that is much lower than the other two phosphate-containing hardening solutions.
2. 當儲存在Hanks’溶液中歷經長時期時,由含磷酸根的硬化溶液所製備的硫酸鈣水泥的CS值適度緩慢地衰減。2. The CS value of the calcium sulfate cement prepared from the phosphate-containing hardening solution is moderately and slowly attenuated when stored in the Hanks' solution for a long period of time.
3. 就儲存在Hanks’溶液中時保持CS值的觀點來看由(NH4 )2 HPO4 硬化溶液所製備的硫酸鈣水泥表現格外地好。經過30天之後,其CS值與1-天的值相比只降低少於20%。3. The calcium sulfate cement prepared from the (NH 4 ) 2 HPO 4 hardening solution is particularly excellent in terms of maintaining the CS value when stored in the Hanks' solution. After 30 days, its CS value decreased by less than 20% compared to the 1-day value.
1. 由(NH4 )2 HPO4 /酒石酸硬化溶液製備的硫酸鈣水泥的CS值比由(NH4 )2 HPO4 製備的硫酸鈣水泥的CS值高18%。1. The calcium sulfate cement prepared from the (NH 4 ) 2 HPO 4 /tartaric acid hardening solution has a CS value 18% higher than the CS value of the calcium sulfate cement prepared from (NH 4 ) 2 HPO 4 .
1. 由含有0.01875 M至0.15 M的磷酸根濃度之K2 HPO4 硬化溶液所製備的硫酸鈣緻密塊樣具有高CS值。當濃度高於0.20 M時,CS大幅降至不可接受的低值。1. A calcium sulfate dense block prepared from a K 2 HPO 4 hardening solution containing a phosphate concentration of 0.01875 M to 0.15 M has a high CS value. When the concentration is higher than 0.20 M, CS drops to an unacceptably low value.
2. 0.075 M的濃度導致最高的CS值。2. The concentration of 0.075 M results in the highest CS value.
1. 由0.075M K2 HPO4 硬化溶液所製備的緻密塊樣品在含磷酸根溶液中比在不含磷酸根溶液中浸漬1天之後具有高許多的CS值。[註釋:HANKS’溶液為含磷酸根溶液]1. A dense block sample prepared from a 0.075 MK 2 HPO 4 hardening solution has a much higher CS value in a phosphate-containing solution than after immersion in a phosphate-free solution for 1 day. [Note: HANKS' solution is a phosphate-containing solution]
2. 不論該浸漬溶液為Hanks’溶液或K2 HPO4 溶液,較低的浸漬溫度(0℃)導致比浸漬溫度(37℃)更高的CS。2. Whether the impregnation solution is a Hanks' solution or a K 2 HPO 4 solution, a lower impregnation temperature (0 ° C) results in a higher CS than the impregnation temperature (37 ° C).
1. 當沉浸在Hanks’溶液中時,由K2 HPO4 硬化溶液所製備的緻密塊樣品(不論濃度為0.0375 M或0.075M)的CS適度緩慢地衰減。經過沉浸16天之後,該等CS值仍舊保持其最初CS值的約70%。1. When immersed in Hanks' solution, CS of dense block samples prepared by K 2 HPO 4 hardening solution (regardless of concentration of 0.0375 M or 0.075 M) moderately decays slowly. After immersion for 16 days, these CS values still maintained about 70% of their original CS value.
研究用的硫酸鈣多孔性硬塊樣品係藉由先於0.35 cc/g的L/P比例下混合CSH及KCl粉末(以重量計1:1)與0.075 M K2 HPO4 硬化溶液以形成KCl/CSH水泥糊狀物。在完全硬化之前,在450 Kgf的壓力之下把該KCl/CSH水泥糊狀物放在鑄模中以將一部分硬化溶液擠出該糊狀物以形成硬化緻密塊。等到從該鑄模移除之後,把該硬化緻密塊樣品沉浸於去離子水中3天使該等造孔粒子能被洗出該緻密塊以形成硫酸鈣多孔性硬塊,接著在50℃的烘箱中乾燥1天。X-射線繞射結果指示沉浸在37℃或4℃的去離子水中3天之後該KCl相完全溶解(由XRD圖案顯示KCl峰消失)。The calcium sulphate porous lumps used in the study were prepared by mixing CSH and KCl powder (1:1 by weight) with 0.075 MK 2 HPO 4 hardening solution at an L/P ratio of 0.35 cc/g to form KCl/CSH. Cement paste. Prior to complete hardening, the KCl/CSH cement paste was placed in a mold under a pressure of 450 Kgf to extrude a portion of the hardening solution out of the paste to form a hardened dense mass. After the removal from the mold, the hardened dense block sample is immersed in deionized water for 3 angels. The pore-forming particles can be washed out of the dense block to form a porous slab of calcium sulfate, followed by drying in an oven at 50 ° C. day. The X-ray diffraction results indicated that the KCl phase was completely dissolved after 3 days of immersion in deionized water at 37 ° C or 4 ° C (the KCl peak disappeared from the XRD pattern).
把一組多孔性硬塊樣品進一步浸漬於37℃或4℃的浸漬溶液((NH4 )2 HPO4 或K2 HPO4 )中一段時間以使該多孔性硬塊的強度提高,接著在50℃的烘箱中乾燥1天。A set of porous lumps samples were further immersed in an impregnation solution ((NH 4 ) 2 HPO 4 or K 2 HPO 4 ) at 37 ° C or 4 ° C for a period of time to increase the strength of the porous lumps, followed by 50 ° C Dry in an oven for 1 day.
另外藉由沉浸在CaCl2 溶液中1至3天處理另一組樣品以進一步增進該等多孔性樣品的強度。Another set of samples was further treated by immersing in a CaCl 2 solution for 1 to 3 days to further enhance the strength of the porous samples.
1. 沉浸在4℃去離子水(4.8 MPa)中的多孔性硬塊樣品的CS值比沉浸在37℃去離子水(2.8 MPa)中的多孔性硬塊樣品的CS值高71%。1. The CS value of the porous lumps sample immersed in 4 ° C deionized water (4.8 MPa) was 71% higher than the CS value of the porous lumps sample immersed in 37 ° C deionized water (2.8 MPa).
1. 在兩種浸漬溶液中,當該浸漬溶液的濃度提高時CS值大幅提高。1. In both impregnation solutions, the CS value increases significantly as the concentration of the impregnation solution increases.
2. 浸漬1天之後,CS在2M(NH4 )2 HPO4 中提高46%而且在2M K2 HPO4 浸漬溶液中提高29%。浸漬3天之後,該CS在2M K2 HPO4 浸漬溶液中提高多達113%。2. After 1 day of immersion, CS was increased by 46% in 2M (NH 4 ) 2 HPO 4 and by 29% in 2M K 2 HPO 4 impregnation solution. After 3 days of immersion, the CS increased by as much as 113% in the 2M K 2 HPO 4 impregnation solution.
為了進一步增進該等多孔性硬塊樣品的強度,把具有5.0 MPa(對照組)的CS值之硫酸鈣多孔性硬塊樣品沉浸在處於不同條件之下的CaCl2 溶液中。In order to further enhance the strength of the porous hard block samples, a calcium sulfate porous hard block sample having a CS value of 5.0 MPa (control) was immersed in a CaCl 2 solution under different conditions.
1. 經過CaCl2 處理之後,該CS在所有條件之下均大幅提高。1. After treatment with CaCl 2 , the CS is greatly improved under all conditions.
2. 在2M CaCl2 中處理3天(從5.0 MPa至21.1 MPa,增加322%)及3M CaCl2 中處理3天(從5.0 MPa至25.1 MPa,增加402%)時發現CS的最大提昇。Found that the maximum lift of the CS process 2. 3 days 2M CaCl 2 (from 5.0 MPa to 21.1 MPa, 322% increase), and 3M CaCl 2 in 3 days (from 5.0 MPa to 25.1 MPa, 402% increase).
Claims (26)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW099135637A TWI487684B (en) | 2010-10-19 | 2010-10-19 | Method for preparing a hardened calcium sulfate dihydrate block and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW099135637A TWI487684B (en) | 2010-10-19 | 2010-10-19 | Method for preparing a hardened calcium sulfate dihydrate block and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201217297A TW201217297A (en) | 2012-05-01 |
| TWI487684B true TWI487684B (en) | 2015-06-11 |
Family
ID=46552166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW099135637A TWI487684B (en) | 2010-10-19 | 2010-10-19 | Method for preparing a hardened calcium sulfate dihydrate block and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI487684B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030135283A1 (en) * | 2001-12-21 | 2003-07-17 | Etex Corporation | Machinable preformed calcium phosphate bone substitute material implants |
| US20050029701A1 (en) * | 2003-08-05 | 2005-02-10 | Cana Lab Corporation | Method for making a molded calcium phosphate article |
| US20050267604A1 (en) * | 2004-05-25 | 2005-12-01 | Calcitec, Inc. | Dual function prosthetic bone implant and method for preparing the same |
| CN1961973A (en) * | 2005-11-09 | 2007-05-16 | 同济大学 | A novel nano bone repair material and preparation method thereof |
-
2010
- 2010-10-19 TW TW099135637A patent/TWI487684B/en active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030135283A1 (en) * | 2001-12-21 | 2003-07-17 | Etex Corporation | Machinable preformed calcium phosphate bone substitute material implants |
| US20050029701A1 (en) * | 2003-08-05 | 2005-02-10 | Cana Lab Corporation | Method for making a molded calcium phosphate article |
| US20050267604A1 (en) * | 2004-05-25 | 2005-12-01 | Calcitec, Inc. | Dual function prosthetic bone implant and method for preparing the same |
| CN1961973A (en) * | 2005-11-09 | 2007-05-16 | 同济大学 | A novel nano bone repair material and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201217297A (en) | 2012-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5441869B2 (en) | Bone cement material and biosorbable hardened bone cement composite formed thereby | |
| Sun et al. | Fast setting calcium phosphate cement-chitosan composite: mechanical properties and dissolution rates | |
| WO2004094335A1 (en) | Calcium phosphate cement, use and preparation thereof | |
| US8591645B2 (en) | Hydraulic cements with optimized grain size distribution, methods, articles and kits | |
| TWI275386B (en) | Methods for preparing medical implants from calcium phosphate cement and medical implants | |
| CN1058689C (en) | Porous calcium phosphate cement containing pore-creating agent | |
| TWI487684B (en) | Method for preparing a hardened calcium sulfate dihydrate block and use thereof | |
| CN109331223B (en) | Medicine-carrying bioactive glass composite calcium phosphate bone cement and application thereof | |
| CN103096713B (en) | Method for preparing a hardened calcium sulfate dihydrate block and use thereof | |
| Wang et al. | Deriving fast setting properties of tetracalcium phosphate/dicalcium phosphate anhydrous bone cement with nanocrystallites on the reactant surfaces | |
| US20120093771A1 (en) | Method for preparing a hardened calcium sulfate dihydrate block and use thereof | |
| Sato et al. | Preparation of injectable hydroxyapatite/collagen paste using sodium alginate and influence of additives | |
| EP2450064B1 (en) | Bone Cement Formula and Bioresorbable Hardened Bone Cement Composites Prepared with the Same | |
| CN104107455B (en) | A kind of bone cement and its slurry | |
| JP6414949B2 (en) | Self-curing chitosan-containing calcium phosphate composition, kit for producing the composition, and production method | |
| JP2013540039A5 (en) | ||
| CN1221293C (en) | Two-phase alpha-tricalcium phosphate/oxyhydrogen-base apatite bone cement and its preparing process | |
| CN116212117B (en) | Strontium magnesium sustained-release apatite bioactive bone cement and its preparation process | |
| CN101223105B (en) | Process for the preparation of a biomimetic bone substitute and its uses | |
| RU2623211C1 (en) | Cement for bone surgery and method of its obtaining | |
| TWI453174B (en) | Bone cement formula and bioresorbable hardened bone cement composites prepared with the same | |
| CN100340307C (en) | Method for manufacturing porous ceramic bone filling material | |
| JP2018038590A (en) | Bioactive cement paste, kit for producing bioactive cement, bioactive cement paste and method for producing the same | |
| CN118619225A (en) | A calcium phosphate porous scaffold with special surface morphology and adjustable topological structure, and preparation method and use thereof | |
| JP2007525240A (en) | Calcium phosphate cement and its usage and formulation. |